Steven Cohen's DAWN Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 31,938 shares of Day One Biopharmaceuticals, Inc. (DAWN) worth $684,751, representing 0.00% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in DAWN, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2024, adding 470,247 shares. Largest reduction occurred in Q3 2024, reducing 470,247 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Day One Biopharmaceuticals (DAWN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Day One Biopharmaceuticals (DAWN) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -124,268 | Reduce 79.55% | 31,938 | $21.44 |
| Q4 2025 | +156,206 | New Buy | 156,206 | $9.32 |
| Q3 2025 | -391,280 | Sold Out | 0 | $0.00 |
| Q2 2025 | +391,280 | New Buy | 391,280 | $6.50 |
| Q3 2024 | -470,247 | Sold Out | 0 | $0.00 |
| Q2 2024 | +470,247 | New Buy | 470,247 | $13.78 |
| Q1 2024 | -88,000 | Sold Out | 0 | $0.00 |
| Q4 2023 | -456,560 | Reduce 83.84% | 88,000 | $14.60 |
| Q3 2023 | +413,560 | Add 315.69% | 544,560 | $12.27 |
| Q2 2023 | +131,000 | New Buy | 131,000 | $11.94 |
| Q1 2023 | -461,631 | Sold Out | 0 | $0.00 |
| Q4 2022 | +461,631 | New Buy | 461,631 | $21.52 |
Steven Cohen's Day One Biopharmaceuticals Investment FAQs
Steven Cohen first purchased Day One Biopharmaceuticals, Inc. (DAWN) in Q4 2022, acquiring 461,631 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Day One Biopharmaceuticals, Inc. (DAWN) for 12 quarters since Q4 2022.
Steven Cohen's largest addition to Day One Biopharmaceuticals, Inc. (DAWN) was in Q2 2024, adding 470,247 shares worth $6.48 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 31,938 shares of Day One Biopharmaceuticals, Inc. (DAWN), valued at approximately $684,751.
As of the Q1 2026 filing, Day One Biopharmaceuticals, Inc. (DAWN) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Day One Biopharmaceuticals, Inc. (DAWN) was 544,560 shares, as reported at the end of Q3 2023.